AI Automated Translation.

Font Size

Share

Bigen Cell, 'VT-EBV-N' Designated as an Advanced Biopharmaceutical Subject to Expedited Review by the Ministry of Food and Drug Safety

Bigen Cell, 'VT-EBV-N' Designated as an Advanced Biopharmaceutical Subject to Expedited Review by the Ministry of Food and Drug Safety

Bigen Cell announced on the 17th that its NK/T-cell lymphoma treatment, 'VT-EBV-N', has been designated as an advanced biopharmaceutical subject to expedited review by the Ministry of Food and Drug Safety.

Bigen Cell's 'VT-EBV-N' is a T-cell therapy being developed for the indication of 'EBV-positive extranodal NK/T-cell lymphoma,' a rare, refractory blood cancer with a relatively high recurrence rate. The company applied for designation as an advanced biopharmaceutical subject to expedited review in June.

The Ministry of Food and Drug Safety's expedited review designation system for advanced biopharmaceuticals provides benefits to treatments that meet criteria such as being intended for the treatment of severe, life-threatening diseases or rare diseases for which no alternative therapies exist. Designated products gain eligibility to apply for conditional marketing authorization and can receive benefits including customized reviews by a dedicated review team and priority review.

Accordingly, Bigen Cell's 'VT-EBV-N' has secured the regulatory foundation to pursue conditional marketing authorization based on clinical trial results, even before the completion of confirmatory clinical trials. Conditional marketing authorization is a system that grants approval for pharmaceuticals that have demonstrated a certain level of clinical efficacy, subject to conditions such as additional post-marketing clinical trials. This can enhance the possibility of early commercialization of new drugs.

In addition, designated advanced biopharmaceutical products are operated with the goal of completing review within 90 business days, which is shorter than the standard 120-business-day review period applied to general products. The time required for marketing authorization may be shortened.

Bigen Cell's 'VT-EBV-N' is an autologous blood-derived antigen-specific T-cell therapy. In Phase 2 clinical trials, it statistically significantly demonstrated improved 2-year disease-free survival (DFS) compared to the control group, achieving its primary endpoint. The 4-year follow-up results disclosed at the American Society of Clinical Oncology (ASCO 2026) on May 30 showed that both an overall survival rate (OS) of 100% and a disease-free survival rate (DFS) of 95.0% were maintained.

Ki Gyeong-seok, CEO of Bigen Cell, stated, "The expedited review designation is the result of regulatory authorities confirming the therapeutic value of 'VT-EBV-N' and the unmet medical need." He added, "We will utilize the shortened review process to prepare for conditional marketing authorization without any issues while accelerating discussions on global technology transfer."

"This article was translated using AI and may differ slightly from the original."